India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Rhythm Pharmaceuticals' lone approved product currently generates minimal sales. If you're interested in capitalizing on the ...

Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and ...

Pharmaceutical giant Cipla plans to enter India's weight management sector, while also bolstering its central nervous system ...

Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Sales of anti-obesity drugs like Mounjaro and Wegovy are seeing a jump due to a surge in popularity, Business Standard ...

Sales of anti-obesity drugs like Mounjaro and Wegovy are seeing a jump due to a surge in popularity, Business Standard ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for market share, data from research firm Pharmarack showed on Monday.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.